Irla, N; Yawalkar, N (2009). Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology, 219(4), pp. 353-6. Basel: Karger 10.1159/000252853
|
Text
000252853.pdf - Published Version Available under License Publisher holds Copyright. Download (386kB) | Preview |
BACKGROUND: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients' quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor alpha with high affinity and specificity. OBSERVATIONS: We report two cases of rapid improvement in nail psoriasis under adalimumab monotherapy with maintained effectiveness despite intermittent treatment as well as long remission after therapy discontinuation. CONCLUSION: The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Yawalkar, Nikhil |
ISSN: |
1018-8665 |
ISBN: |
19851059 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 15:09 |
Last Modified: |
21 Jun 2023 11:50 |
Publisher DOI: |
10.1159/000252853 |
PubMed ID: |
19851059 |
Web of Science ID: |
000272328700013 |
BORIS DOI: |
10.48350/30395 |
URI: |
https://boris.unibe.ch/id/eprint/30395 (FactScience: 193768) |
Actions (login required)
 |
Edit item |